pharmaphorum2y
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure
Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...
pharmaphorum4y
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney disease
The FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new use, to reduce the risk of renal failure and cardiovascular death in people with chronic ...
The American Journal of Managed Care2y
IMPROVING OUTCOMES IN HEART FAILURE REGARDLESS OF LVEF
JARDIANCE is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR <30 mL/min/1.73 m2. JARDIANCE is likely to be ineffective in this setting ...